Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Jerome H. Goldschmidt et al.|Blood|2023Cited by 42
Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)Christopher A. Yasenchak, J.T. Beck, Rodolfo Bordoni et al.|Blood|2022Cited by 2